PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow PTCT
PTC Therapeutics, Inc. (PTCT) P/E ratio
PTC Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 9.0× (November 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 8.6× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 8.6× | 35.32% |
| Sep 2025 | 6.4× | 4.87% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| COGT Cogent Biosciences, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. | n/m |
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| MIRM Mirum Pharmaceuticals, Inc. compare | n/m |
| TVTX Travere Therapeutics, Inc. compare | n/m |
| CGON CG Oncology, Inc. compare | n/m |
| SRRK Scholar Rock Holding Corporation compare | n/m |
| CRSP CRISPR Therapeutics AG compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)